More on TAK
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $17.44 |
|
|||
| Open | $17.44 | ||||
| 52 Wk High | $0.55 | ||||
| 52 Wk Low | $0.55 | ||||
| Day High | $17.44 | ||||
| Day Low | $17.44 | ||||
| P/E | N/A | ||||
| EPS | $-0.20 | ||||
| Volume | 10 | ||||
- Takeda psoriasis drug shows skin clearance in Phase 3 trials
- Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Pignagnoli Agosti Marcello
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Furney Natalie Anne Marie
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Ricci Gabriele
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Shannon Elaine Mary
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Ibrahim Ramy Riad Ahmed
Entities mentioned with TAK
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- Dividend | View Related Stories »
- ARK | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
